Medicine

Ukrainian health officials have released the list of conditions that will qualify patients for the country’s new medical cannabis program.

Having access to legal medical cannabis in all 50 U.S. states could save Americans up to $29 billion per year in reduced healthcare expenditures, according to a recent study.

A recent survey by Germany-based medical cannabis company Bloomwell GmBh found that 94% of respondents who consumed cannabis said they did so for at least one medical or health reason.

The Oklahoma Court of Criminal Appeals has ruled that women registered with the state’s medical cannabis program who consume cannabis while pregnant cannot be prosecuted for child neglect.

The head of UCLA’s Semel Institute for Neuroscience and Human Behavior is aiming to convert the institute’s top floor into a rooftop garden, or “living laboratory,” designed to study and facilitate psychedelic-assisted therapy.

The largest school district in Kentucky last week approved a policy allowing students to use prescribed medical cannabis treatments while at school.

British researchers investigating the efficacy of medical cannabis for older patients said that people aged 65+ who are prescribed medical cannabis report experiencing “significant improvements across all measures of well-being.”

Three pharmaceutical companies in Zimbabwe have started to manufacture cannabis medicines under the country’s five-year-old industrial hemp reforms.

Vermont Gov. Phil Scott (R) has allowed a medical cannabis expansion bill to become law without his signature; the shift will give patients access to higher potency products without a sales tax.

Connecticut officials have approved two new conditions — autism spectrum disorder and female orgasmic difficulty/disorder — as qualifying conditions for the state medical cannabis program.

The publicly traded and internationally licensed cannabis company Kaya Holdings Inc. announced this week that it has received a license to administer therapeutic psilocybin products in Oregon.

According to a new study compiled by UK researchers, psilocybin — the naturally occurring psychedelic in so-called “magic mushrooms” — shows promise as an effective treatment for depression.

A recent study found that non-medical cannabis use is “significantly associated with 96% decreased odds” of experiencing cognitive decline in adults aged 45 and older.

A recent review published by a group of Canadian scientists suggests that cannabinoids could play a role in preventing and treating COVID-19 and Long-COVID.

Researchers with the Johns Hopkins University School of Medicine, with the support of a $10 million federal grant, are set to track 10,000 U.S. cannabis patients from the start of their medical cannabis journey through at least a year to better understand the efficacy and effects of cannabis medicine.

In a recent paper, researchers have advocated for equitable and inclusive practices in cannabis research, addressing the historical and ongoing disparities in enforcement and the industry’s profit distribution.

Five years after the United Kingdom legalized medical cannabis products for use on the National Health Service (NHS), the government still has not funded the trials that would allow physicians to prescribe cannabis products.

A recent study found that about 80% of people who consume cannabis to help with sleep quit using prescription and over-the-counter sleep aids such as melatonin and benzodiazepines.

Lawmakers in Japan’s House of Representatives have passed a bill to legalize cannabis-derived pharmaceuticals. The bill would also establish legal restrictions on general cannabis use, which was not previously referenced under federal law.

The medical cannabis market in Ohio is expected to hit $520 million this year, according to cannabis industry intelligence firm BDSA, which also predicts the state’s combined cannabis markets will total $820 million in 2025.

A recent study published in the journal Psychedelic Medicine found that a majority of American Psychiatric Association members either moderately or strongly believed that hallucinogens show promise in treating psychiatric conditions.